Streetbeat News

ACON

Aclarion, Inc.

https://www.aclarion.com

Industry

Medical - Healthcare Information Services

Aclarion, Inc., a healthcare technology company, develops software application for magnetic resonance spectroscopy (MRS) in the United States. It offers NOCISCAN-LS Post-Processor suite comprising NOCICALC-LS that receives and processes the acquired disc MRS data to calculate levels of degenerative pain biomarkers; and NOCIGRAM-LS, a clinical decision support software. The company was formerly known as Nocimed, Inc. and changed its name to Aclarion, Inc. in December 2021. Aclarion, Inc. was founded in 2008 and is based in San Mateo, California.

Open

0.20

Mkt cap

1.9M

Volume

673K

High

0.20

P/E Ratio

-0.05

52-wk high

7.39

Low

0.19

Div yield

N/A

52-wk low

0.16

U.S. stocks showed modest gains with the Nasdaq Composite up by 50 points. Domino's Pizza Inc. reported better-than-expected Q4 earnings, raising its dividend by 25% and authorizing a $1 billion stock buyback. Akili, Inc., ZyVersa Therapeutics, Inc., and MicroCloud Hologram Inc. saw significant stock price increases due to positive clinical trial results and market movements, respectively. Conversely, Aclarion, Inc., Intuitive Machines, Inc., and Brera Holdings PLC experienced notable declines in their stock prices.

Portfolio Pulse from Avi Kapoor

February 26, 2024 | 2:48 pm

Aclarion Inc (NASDAQ:ACON) shares plummeted by 62.5% to $0.34 after announcing a public offering of 5.175 million units at $0.58 per unit, aiming to raise about $3.0 million. The offering includes shares of common stock (or pre-funded warrants) and two common warrants, with Maxim Group LLC as the placement agent. The significant drop in ACON's stock price follows a 94.07% decrease over the past year, with the stock hitting a 52-week low of $0.87 and a high of $37.92. The current RSI indicates oversold conditions.

Portfolio Pulse from Henry Khederian

February 26, 2024 | 2:28 pm

Aclarion, Inc. has announced the pricing of its offering, consisting of 5,175,000 units at a price of $0.58 per unit. This move is aimed at raising capital for the company.

Portfolio Pulse from Benzinga Newsdesk

February 26, 2024 | 2:16 pm

In Monday's pre-market session, several healthcare stocks showed significant movement. ZyVersa Therapeutics, Agiliti, NeuBase Therapeutics, ImmunityBio, Monopar Therapeutics, and Altimmune were among the gainers with notable percentage increases in their stock prices. Conversely, ThermoGenesis Holdings, Aclarion, Telesis Bio, Venus Concept, Motus GI Holdings, and Cogent Biosciences experienced declines. These movements reflect the dynamic nature of the healthcare sector in the stock market.

Portfolio Pulse from Benzinga Insights

February 26, 2024 | 1:06 pm

Health care stocks experienced significant movements in Friday's intraday session, with Maravai LifeSciences leading the gainers after reporting Q4 earnings, and ModivCare heading the losers also following its Q4 earnings release. Other notable movers include Ocean Biomedical, Monopar Therapeutics, and Gyre Therapeutics on the gainers' side, and Venus Concept, SeaStar Medical Holding, and ImmunityBio among the losers.

Portfolio Pulse from Benzinga Insights

February 23, 2024 | 5:31 pm

Health care stocks experienced significant movements in Thursday's intraday session. Monopar Therapeutics and Calidi Biotherapeutics led the gainers with over 75% increases in their stock prices, while Synaptogenix and Motus GI Holdings were among the top losers, with over 20% declines. Notably, Amylyx Pharma and SenesTech released their Q4 earnings, influencing their stock movements.

Portfolio Pulse from Benzinga Insights

February 22, 2024 | 5:31 pm

Aclarion Inc has filed an amended prospectus with the SEC for an offering on a best efforts basis of up to 3.9 million units, with each unit comprising one share of common stock and one warrant to purchase an additional share.

Portfolio Pulse from Benzinga Newsdesk

February 21, 2024 | 8:14 pm

Aclarion has announced the completion of recent financing transactions, which have effectively reduced its debt and increased its available cash. This strategic financial maneuver is aimed at strengthening the company's balance sheet and enhancing its financial flexibility for future operations and investments.

Portfolio Pulse from Benzinga Newsdesk

February 05, 2024 | 1:03 pm

Panbela Therapeutics, Inc. (NASDAQ:PBLA) shares plummeted by 65.5% to $1.47 after announcing a public offering priced at approximately $9 million. Other stocks experienced significant movements in Monday's mid-day session, with various companies showing notable gains and losses. Gainers included Palisade Bio, Inc. (NASDAQ:PALI), OneMedNet Corporation (NASDAQ:ONMD), and Revelation Biosciences, Inc. (NASDAQ:REVB), among others. Losers featured SMX (Security Matters) Public Limited Company (NYSE:SMX), Inspire Veterinary Partners, Inc. (NASDAQ:IVP), and Bullfrog AI Holdings, Inc. (NASDAQ:BFRG), among others.

Portfolio Pulse from Avi Kapoor

January 29, 2024 | 7:09 pm

In Monday's pre-market session, several healthcare stocks experienced significant movements. OneMedNet (ONMD) saw a substantial increase of 172.1%, while Panbela Therapeutics (PBLA) faced a sharp decline of 62.5%. Other notable gainers include Jin Medical International (ZJYL), NovaBay Pharmaceuticals (NBY), Longeveron (LGVN), Palisade Bio (PALI), and Science 37 Hldgs (SNCE). Conversely, Aclarion (ACON), HOOKIPA Pharma (HOOK), Onconetix (ONCO), Elicio Therapeutics (ELTX), and Checkpoint Therapeutics (CKPT) were among the losers.

Portfolio Pulse from Benzinga Insights

January 29, 2024 | 1:06 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.